The companies behind the molecules

Pharma, biotech & telehealth in peptide therapy

The firms whose decisions shape peptide-therapy access — GLP-1 manufacturers, compounding telehealth players, clinical-stage challengers, and a few private-side longevity outliers. Live ticker for public names; brief, plain-language descriptions for everyone.

Corporate decisions determine availability far more directly than the science does. A shortage declaration opens legal compounding; declaring the shortage resolved closes it again, which is precisely what happened to compounded tirzepatide and semaglutide across 2025. Patent expiry, manufacturing capacity, pricing and which trials a sponsor chooses to run all decide what a patient can actually obtain, and at what price.

The same applies in reverse. When a sponsor halts a programme, the compound does not always disappear — it often reappears on the grey market with the trial that stopped it going unmentioned. Knowing who ran a study, and why it ended, is frequently the most load-bearing safety information available about a peptide.

Prices via Yahoo Finance, refreshed every 5 minutes. We don't give investment advice — see funding & affiliate disclosure.

Tickers and prices sourced from Yahoo Finance unofficial chart endpoint. We are not a financial-data provider; data is provided as-is for editorial context. Verify prices with your broker before making any decision.